01:22:44 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2024-02-14 Bokslutskommuniké 2023
2023-11-15 Kvartalsrapport 2023-Q3
2023-08-23 Kvartalsrapport 2023-Q2
2023-05-16 Kvartalsrapport 2023-Q1
2023-05-11 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-23 Kvartalsrapport 2022-Q3
2022-08-24 Kvartalsrapport 2022-Q2
2022-05-16 Kvartalsrapport 2022-Q1
2022-05-13 Ordinarie utdelning NYKD 0.00 NOK
2022-05-12 Årsstämma 2022
2022-03-31 Bokslutskommuniké 2021
2021-12-22 Extra Bolagsstämma 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-12 Kvartalsrapport 2021-Q1
2021-05-06 Ordinarie utdelning NYKD 0.00 NOK
2021-05-05 Årsstämma 2021
2021-04-21 Bokslutskommuniké 2020
2020-11-17 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-07-07 Split NYKD 1:5
2020-07-06 Extra Bolagsstämma
2020-05-12 Kvartalsrapport 2020-Q1
2020-04-22 Extra Bolagsstämma


ListaOB Match
Nykode Therapeutics är verksamma inom bioteknik. Bolaget är idag specialiserade inom forskning och utveckling av immunologiska terapier och vacciner. Lösningarna används huvudsakligen för behandling av patienter med cancersjukdomar samt övriga allvarliga hälsotillstånd som kräver långsiktig behandling. Störst verksamhet återfinns inom den europeiska marknaden.
2022-04-08 19:00:00
Oslo, Norway, April 8, 2022 - Nykode Therapeutics AS (Euronext Growth (Oslo):
NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and
development of vaccines and novel immunotherapies, today announced preclinical
data from its second-generation Vaccibody Antigen-Presenting Cell
(APC)-targeting vaccine technology, which incorporates immune-stimulatory
cytokines. The data will be presented in a poster session at the 2022 American
Association for Cancer Research (AACR) Annual Meeting on Tuesday, April 12,
2022, from 1:30 p.m. - 5:00 p.m. ET.

"The preclinical data reported at AACR highlights that Nykode's unique vaccines
co-expressed with immune-stimulatory proteins can produce a nearly three-fold
boost in anti-tumor immune cell response in comparison to the first-generation
platform. The research showcases the advantages of Nykode's APC-targeted
delivery of tumor specific antigens and its ability to successfully induce a
powerful immune response against tumor cells, overcoming a historical challenge
in the development of cancer vaccines. We look forward to continued innovation
in our platform as we advance our pipeline of vaccine candidates through the
clinic," said Mikkel Pedersen, Chief Scientific Officer of Nykode Therapeutics.

The preclinical results demonstrate that the co-expression of the Vaccibody
molecule and immune-stimulatory cytokines enhances anti-tumor immune responses,
leads to an expansion of antigen-specific polyfunctional effector T cells and
superior tumor control. In addition, the data demonstrate that the
second-generation platform enhances APC infiltration, proliferation and
differentiation, measured by live CD45+ infiltrated cells and the proportion of
DCs in live CD45+ cells, including cDC1.

Details of the poster presentation are as follows:

Abstract #: 2232
Title: A novel and versatile cytokine empowered DNA vaccine platform with
superior immune activating potential
Authors: Beraas, et al.
Session Title: Vaccines: Oncolytic and Prophylactic
Session Date and Time: Tuesday, April 12, 2022 | 1:30 p.m. - 5:00 p.m. ET

The poster presentation is available in the AACR 2022 Annual Meeting program
(www.aacr.org/meeting/aacr-annual-meeting-2022) and in the Scientific Papers and
Presentations section of the Company's website

Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of vaccines and novel immunotherapies for the
treatment of cancer and infectious diseases. Nykode's modular vaccine technology
specifically targets antigens to Antigen Presenting Cells, which are essential
for inducing rapid, strong and long-lasting antigen specific immune responses
and eliciting efficacious clinical responses.

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus 16 induced malignancies which is in Phase 2
for the treatment of cervical cancer